```json
{
"content": [
{
"type": "paragraph",
"content": "North America leads the Ceftazidime and Avibactam Sodium for Injection market, accounting for 40% of global demand. Robust adoption of advanced therapies, stringent regulatory frameworks promoting antibiotic stewardship, and high healthcare infrastructure maturity drive its dominance. The region’s aging population and rising healthcare investments further fuel market growth."
},
{
"type": "paragraph",
"content": "Europe holds a 25% market share, supported by strong R&D ecosystems, government-funded pharmaceutical innovation, and proactive policies to combat antimicrobial resistance. Public-private partnerships and high patient awareness are critical enablers, though pricing pressures may temper expansion."
},
{
"type": "paragraph",
"content": Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 8.5% through 2030. Factors include rising prevalence of drug-resistant infections, improving healthcare access in emerging economies, and strategic investments in biosimilar production. China and India are pivotal, with evolving regulatory standards aligning with global benchmarks."
},
{
"type": "paragraph",
"content": "Latin America and Middle East & Africa collectively represent 10% of the market. In Latin America, public health initiatives and infrastructure upgrades in Brazil and Mexico are key growth levers. MEA’s market is driven by increasing antimicrobial resistance and growing healthcare sector investments, though limited diagnostic capabilities and healthcare funding pose challenges."
}
],
"worldMapData": {
"regions": [
{ "name": "North America", "value": 40 },
{ "name": "Europe", "value": 25 },
{ "name": "Asia Pacific", "value": 25 },
{ "name": "Latin America", "value": 8 },
{ "name": "Middle East & Africa", "value": 2 }
]
}
}
```
